NIJMEGEN, NETHERLANDS, May 7, 2024 /EINPresswire.com/ -- Simmunext Biotherapeutics is proud to announce its participation in the prestigious BioEquity Europe Meeting, scheduled to be held from May 12 to 14 in San Sebastian, Spain. As a leading biotechnology company dedicated to advancing the frontiers of immunotherapy, Simmunext is set to present its groundbreaking research and development initiatives on immunofilaments, aimed at revolutionizing the treatment landscape for complex disorders.
Under the leadership of CEO Henri Theunissen, Simmunext Biotherapeutics will present its latest advancements in harnessing the power of the immune system to combat cancer. With a focus on the use of immunofilaments in ex vivo and in vivo (CAR) T cell therapies, the company's presentations promise to offer valuable insights into the future of healthcare.
"We are thrilled to participate in the BioEquity Europe Meeting and share our vision for the future of immunotherapy," said Henri Theunissen, CEO of Simmunext Biotherapeutics. "Our team is committed to pushing the boundaries of scientific innovation to deliver transformative therapies for patients worldwide."
For media inquiries or to schedule interviews with Henri Theunissen during the BioEquity Europe Meeting, please contact:
Henri Theunissen
CEO, Simmunext Biotherapeutics
Email: henri@simmunext.com
About Simmunext Biotherapeutics:
Simmunext Biotherapeutics is a leading biotechnology company focused on leveraging the immune system to develop novel treatments for a wide range of diseases such as cancer, (auto)immune disorders, and infectious disease. With a mission to improve patient outcomes, Simmunext is dedicated to pioneering innovative therapies through cutting-edge research and strategic collaborations. For more information, visit www.simmunext.com.
Under the leadership of CEO Henri Theunissen, Simmunext Biotherapeutics will present its latest advancements in harnessing the power of the immune system to combat cancer. With a focus on the use of immunofilaments in ex vivo and in vivo (CAR) T cell therapies, the company's presentations promise to offer valuable insights into the future of healthcare.
"We are thrilled to participate in the BioEquity Europe Meeting and share our vision for the future of immunotherapy," said Henri Theunissen, CEO of Simmunext Biotherapeutics. "Our team is committed to pushing the boundaries of scientific innovation to deliver transformative therapies for patients worldwide."
For media inquiries or to schedule interviews with Henri Theunissen during the BioEquity Europe Meeting, please contact:
Henri Theunissen
CEO, Simmunext Biotherapeutics
Email: henri@simmunext.com
About Simmunext Biotherapeutics:
Simmunext Biotherapeutics is a leading biotechnology company focused on leveraging the immune system to develop novel treatments for a wide range of diseases such as cancer, (auto)immune disorders, and infectious disease. With a mission to improve patient outcomes, Simmunext is dedicated to pioneering innovative therapies through cutting-edge research and strategic collaborations. For more information, visit www.simmunext.com.
Henri Theunissen
Simmunext Biotherapeutics
henri@simmunext.com